These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21134973)

  • 1. The cultural adaptability of intermediate measures of functional outcome in schizophrenia.
    Velligan DI; Rubin M; Fredrick MM; Mintz J; Nuechterlein KH; Schooler NR; Jaeger J; Peters NM; Buller R; Marder SR; Dube S
    Schizophr Bull; 2012 May; 38(3):630-41. PubMed ID: 21134973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A qualitative assessment of cross-cultural adaptation of intermediate measures for schizophrenia in multisite international studies.
    Gonzalez JM; Rubin M; Fredrick MM; Velligan DI
    Psychiatry Res; 2013 Apr; 206(2-3):166-72. PubMed ID: 23167987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reliability and validity of the MATRICS functional assessment battery.
    Velligan DI; Fredrick M; Mintz J; Li X; Rubin M; Dube S; Deshpande SN; Trivedi JK; Gautam S; Avasthi A; Kern RS; Marder SR
    Schizophr Bull; 2014 Sep; 40(5):1047-52. PubMed ID: 24214931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.
    Keefe RS; Poe M; Walker TM; Kang JW; Harvey PD
    Am J Psychiatry; 2006 Mar; 163(3):426-32. PubMed ID: 16513863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive Assessment Interview (CAI): Validity as a co-primary measure of cognition across phases of schizophrenia.
    Ventura J; Subotnik KL; Ered A; Hellemann GS; Nuechterlein KH
    Schizophr Res; 2016 Apr; 172(1-3):137-42. PubMed ID: 26852403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
    Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study.
    Harvey PD; Raykov T; Twamley EW; Vella L; Heaton RK; Patterson TL
    Am J Psychiatry; 2011 Nov; 168(11):1195-201. PubMed ID: 21572166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia.
    Green MF; Schooler NR; Kern RS; Frese FJ; Granberry W; Harvey PD; Karson CN; Peters N; Stewart M; Seidman LJ; Sonnenberg J; Stone WS; Walling D; Stover E; Marder SR
    Am J Psychiatry; 2011 Apr; 168(4):400-7. PubMed ID: 21285142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.
    Keefe RS; Davis VG; Spagnola NB; Hilt D; Dgetluck N; Ruse S; Patterson TD; Narasimhan M; Harvey PD
    Eur Neuropsychopharmacol; 2015 Feb; 25(2):176-84. PubMed ID: 25028065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the validity of measures of social cognitive bias in schizophrenia: Additional results from the Social Cognition Psychometric Evaluation (SCOPE) study.
    Buck BE; Pinkham AE; Harvey PD; Penn DL
    Br J Clin Psychol; 2016 Nov; 55(4):441-454. PubMed ID: 27168196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of schizophrenia in black Xhosa-speaking and white English-speaking South Africans.
    Ensink K; Robertson BA; Ben-Arie O; Hodson P; Tredoux C
    S Afr Med J; 1998 Jul; 88(7):883-7. PubMed ID: 9698718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The brief negative symptom scale in translation: A review of psychometric properties and beyond.
    Tatsumi K; Kirkpatrick B; Strauss GP; Opler M
    Eur Neuropsychopharmacol; 2020 Apr; 33():36-44. PubMed ID: 32081498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Positive and Negative Syndrome Scale--Spanish adaptation.
    Kay SR; Fiszbein A; Vital-Herne M; Fuentes LS
    J Nerv Ment Dis; 1990 Aug; 178(8):510-7. PubMed ID: 2380697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.
    Reise SP; Ventura J; Keefe RS; Baade LE; Gold JM; Green MF; Kern RS; Mesholam-Gately R; Nuechterlein KH; Seidman LJ; Bilder R
    Psychol Assess; 2011 Mar; 23(1):245-61. PubMed ID: 21381848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia.
    Sarró S; Dueñas RM; Ramírez N; Arranz B; Martínez R; Sánchez JM; González JM; Saló L; Miralles L; San L
    Schizophr Res; 2004 Jun; 68(2-3):349-56. PubMed ID: 15099616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Brazilian standardization of the MATRICS consensus cognitive battery (MCCB): Psychometric study.
    Fonseca AO; Berberian AA; de Meneses-Gaya C; Gadelha A; Vicente MO; Nuechterlein KH; Bressan RA; Lacerda ALT
    Schizophr Res; 2017 Jul; 185():148-153. PubMed ID: 28110814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-cultural adaptation and psychometric properties of the Chinese version of the Functional Remission of General Schizophrenia (FROGS) scale and the four-item version (mini-FROGS) among people with schizophrenia.
    Wang WL; Zhou YQ; Mao YY; Qu P
    Asian J Psychiatr; 2020 Jan; 47():101871. PubMed ID: 31739130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
    Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS).
    Velligan DI; Diamond P; Glahn DC; Ritch J; Maples N; Castillo D; Miller AL
    Psychiatry Res; 2007 May; 151(1-2):55-66. PubMed ID: 17379319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.